Connect with us

Health

Listening to music after 70 may cut dementia risk by nearly 40%, new study suggests

Published

on

Listening to music after 70 may cut dementia risk by nearly 40%, new study suggests

NEWYou can now listen to Fox News articles!

A new study that suggests listening to or playing music could slash the risk of dementia might have you singing a new tune.

Adults over 70 who regularly listen to music were nearly 40% less likely to develop dementia — a group of cognitive disorders that cause a decline in memory, thinking and other mental abilities — according to a new study from Monash University in Melbourne, Australia.

Those who always listened to music showed a 39% lower risk of developing dementia and better memory performance, while those who played instruments had a 35% lower risk. 

STUDY REVEALS WHY ‘SUPER AGERS’ MAINTAIN ‘OUTSTANDING MEMORY’ INTO THEIR 80S

Advertisement

Doing both offered an even greater protective effect against cognitive decline, the researchers, led by Monash honors student Emma Jaffa and Professor Joanne Ryan, found.

Researchers found that seniors who play an instrument or regularly listen to music may have better brain health in later years. (iStock)

“With no cure currently available for dementia, the importance of identifying strategies to help prevent or delay onset of the disease is critical,” Ryan said in a statement.

“Evidence suggests that brain aging is not just based on age and genetics but can be influenced by one’s own environmental and lifestyle choices,” she added.

EVEN SMALL AMOUNTS OF ALCOHOL LINKED TO HIGHER DEMENTIA RISK IN OLDER ADULTS, STUDY SHOWS

Advertisement

More than 10,800 adults aged 70 and older were tracked for several years as part of long-running Australian studies, and they were asked if they always, often, sometimes, rarely or never listened to and play music, according to the paper published last month in the International Journal of Geriatric Psychiatry.

Regularly engaging in both listening to and playing music also reduced the risk of mild cognitive impairment, which is less severe than dementia, by 22%, and was linked to higher scores in overall cognition and episodic memory, which helps people recall everyday events.

Playing a musical instrument later in life could help strengthen memory and thinking skills, scientists say. (iStock)

Dementia affects about 57 million people worldwide, according to the World Health Organization, and the findings suggest music may offer a simple way to help protect cognitive function, but do not prove that it directly prevents dementia.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

“Music activities may be an accessible strategy for maintaining cognitive health in older adults, though causation cannot be established,” the researchers noted.

The overall benefits of music were most pronounced among older adults with higher education levels — those who had completed at least 16 years of schooling — while results were mixed for those with a moderate level of education.

The findings add to growing research showing that creative, social and mentally stimulating hobbies such as music, reading and art may help keep the brain healthy in later life, with a 2022 meta-analysis from the U.S. and Japan reporting similar benefits for older adults who play musical instruments.

Staying mentally and socially active through hobbies like music may help keep the brain healthy. (iStock)

Advertisement

Dr. Morten Scheibye-Knudsen, an associate professor of aging at the University of Copenhagen, cautioned that while mental stimulation is encouraged, the science on it isn’t settled. 

CLICK HERE FOR MORE LIFESTYLE STORIES

“In general, it is advised to train your brain, but the data is actually not that clear,” he recently told BBC Science Focus, noting that studies on activities like music, puzzles or learning new skills have shown mixed results. 

Still, he noted, “There are additional benefits to playing an instrument … including increased social interactions — which has been shown to be very important as we age.”

Advertisement

Fox News Digital has reached out to the study’s authors for comment.

Health

Will Her Daughter Be Safe at Pali High as It Rebuilds From LA Wildfires?

Published

on

Will Her Daughter Be Safe at Pali High as It Rebuilds From LA Wildfires?

One morning just before Christmas, Michelle stood in a Thrifty-Wash, watching her seven loads of laundry tumble and spin. The machine at the Airbnb had broken and flooded the place. It had been a blessing, in a way — Michelle needed this time alone to think.

The night before, Los Angeles Unified School District officials had hosted a Zoom webinar for parents, in which they had promised to present all the evidence that campus was safe. Michelle had gone in with high hopes, maybe even optimism. Afterward, she called it “the Zoom from hell.”

The officials had opened the meeting by announcing that Pali High’s students would go back to campus at the end of January. Michelle had peered at the screen, squinting to make sense of their color-coded maps, charts and checklists as district officials and their third-party contractors used wonky terms to describe what sounded to Michelle like rudimentary decontamination methods: “visual inspections,” “glove tests,” “subjective evaluations for smoke odor” and the copious use of wet wipes.

The “Environmental Concerns” WhatsApp group began pinging with live commentary. “It’s like they’re all hanging out with my insurance company,” one mother typed. “Transparency my a$$,” wrote another.

During the question-and-answer portion, parents flooded the submission box: Why weren’t the porous ceiling tiles removed? (“We did our best to remove any surface contaminants that we could see visually,” one contractor replied.) Did they realize that lithium had been detected in smoke-damaged homes near the school? (“Lithium, we determined, was not going to be a high-priority metal for us,” another contractor explained.) And why hadn’t they tested for benzene, carbon tetrachloride or perchloroethylene — some of which had been found in other Palisades buildings after the fires?

Advertisement

Michelle had a hunch she knew the answer, but she assumed no official would ever admit it. Then the project manager for one of the contractors came on the screen.

“There are hundreds — literally — of different compounds that could be produced during a fire,” he said, “and there are analytical methods that can be very, very precise in sampling for those.” But the problem, he said, was that it “lacks specificity in what we can actually deal with … ”

Michelle had shaken her head in disbelief. The project manager interrupted himself. “That was the wrong way to put that,” he muttered.

This morning, Michelle had waked to some parents on the “Environmental Concerns” chat talking about putting their kids in virtual learning. Others were hoping to transfer. Michelle was fantasizing about protesting the return to campus, even dreaming up the picket signs: “Lead should only be in pencils,” or maybe, “Test on the school, not on the kids.”

Advertisement
Continue Reading

Health

Experimental obesity drug outperforms traditional weight-loss treatments in early research

Published

on

Experimental obesity drug outperforms traditional weight-loss treatments in early research

NEWYou can now listen to Fox News articles!

A new weight-loss drug variation is showing promise in early trials.

Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani.

The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity, inflammation, fat metabolism and liver health.

‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS

Advertisement

The team of researchers, led by Professor Timo D. Muller at Helmoltz Munich, called the drug a quintuple agonist, as it targets five receptor systems.

In a press release, Muller described the drug as a “Trojan horse”: the incretin component — hormones that help regulate blood sugar and appetite — allows it to enter target cells, and once inside, the PPAR “cargo” activates to help the body better use insulin, process fat and reduce inflammation.

The researchers hope the “Trojan horse” effect will allow for lower dosing and fewer side effects. (iStock)

This allows for the dosage of the drug to be lower, which could reduce side effects.

“A major advantage is the amount,” Muller said. “Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower.”

Advertisement

NEW WEIGHT-LOSS SHOT SHOWS MAJOR FAT REDUCTION, BUT EXPERTS URGE CAUTION

The study tested the drug combination in mouse models, including mice with diabetes-induced obesity, insulin resistance and genetic obesity.

In these mice, the compound was found to lower body weight, food intake, fat mass, blood sugar and insulin-related problems more than GLP-1 and GIP alone. It also outperformed semaglutide.

CLICK HERE FOR MORE HEALTH STORIES

The researchers reported that typical gastrointestinal side effects were similar to those seen with existing therapies.

Advertisement

“We see a principle with strong effects in the animal model — now the task is to optimize the approach for humans and move it toward the clinic,” Muller said in the release.

The preclinical study was conducted in mouse models and cannot yet be applied to humans. (iStock)

Dr. Peter Balazs, MD, a hormone and weight-loss specialist practicing in New York and New Jersey, said the drug is designed to target obesity and insulin resistance “at multiple key sites simultaneously, including the brain, pancreas and metabolic tissues.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“This is a novel mechanism because it’s not just relying on a higher dose of an existing drug,” he told Fox News Digital in an interview.

Advertisement

“Current GLP-1 medications are highly effective appetite suppressants, while this quintuple agonist seems to function both as an ‘appetite brake’ and a metabolic engine,” he added.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above” while also “directly improving insulin sensitivity in the liver and muscle, reducing inflammation in adipose tissue and remodeling lipid metabolism,” the expert confirmed.

While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above,” an expert said. (iStock)

“The result may be greater weight loss through a combination of caloric restriction, enhanced fat oxidation and potentially increased central energy expenditure,” Balazs said.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Although the drug provides a “promising direction for the future,” Balazs noted that the study was conducted only on mouse models and there is no human safety or efficacy data, which means the drug cannot yet be recommended for clinical use.

“Additionally, it was conducted over a relatively short period of time, so we cannot draw conclusions about long-term effects,” he added.

Continue Reading

Health

With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win

Published

on

With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win

Over lunch at his golf club in Jupiter, Fla., on the first Saturday of May, President Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.

Eventually Mr. Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the F.D.A. commissioner.

No answer.

Furious, the president then dialed Dr. Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the F.D.A.’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.

The message was received. Less than one week later, the executives got what they wanted.

Advertisement

On Friday, the F.D.A. issued new guidance that could pave the way for major tobacco companies to begin selling flavored vapes and to snare a chunk of the $6 billion e-cigarette market away from illegal Chinese competitors. The new policy bypassed the F.D.A.’s regular rule-making process.

In the intervening week, Dr. Makary continued to argue against approving flavored vapes as support from Mr. Kennedy and others collapsed around him. Health and Human Services Department staff began to draft the new plan, according to two people familiar with the events.

On Tuesday, Dr. Makary resigned, telling associates he could not in good conscience remain the head of an agency that backed such a policy.

Though there is no definitive evidence linking the new guidance to donations or lobbying, the episode represented a clear pivot in the federal government’s longtime approach to the tobacco industry.

Since the 1990s, when states extracted vast payments and other concessions from the major cigarette companies in a nationwide legal settlement, Big Tobacco has been in retreat. Cigarette sales have plummeted, and regulations have mounted as consumers and administrations from both parties embraced public health consensus about the dangers of smoking and nicotine addiction.

Advertisement

Mr. Trump’s first administration initially continued the trend, proposing further restrictions on cigarettes and moving to outlaw flavored vapes over concerns that their rising popularity threatened the health of a generation of adolescents.

But since then, Mr. Trump has enthusiastically welcomed the financial support of the tobacco industry and has courted e-cigarette users as a political constituency.

The new vaping guidance highlights Mr. Trump’s willingness to use his executive authority to prioritize the causes of major corporate donors over public health concerns, taxpayer interests and the judgment of experts, sometimes including those in his own administration.

The president has developed a close relationship with tobacco companies including Altria and Reynolds American, which have donated millions of dollars to his political groups and projects, including his proposed White House ballroom. Their executives attended the lunch at the president’s golf club.

The Department of Health and Human Services, which oversees the F.D.A., referred requests for comment to the White House.

Advertisement

Kush Desai, a White House spokesman, said in a statement that Mr. Trump has pushed to expand access to vapes to help Americans trying to quit smoking.

“The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Mr. Desai said.

Reynolds American and Altria did not respond to questions about their lobbying or the conversation at the lunch.

It was attended by Jeff Raborn, a top executive at Reynolds, and Phil Park and Todd Walker of Altria, according to the people familiar with the meeting. Also attending were Brian Ballard and Rich Haselwood, lobbyists for the firm Ballard Partners, which represents Reynolds and helped marshal a sophisticated and expensive influence campaign that culminated in the new vaping guidance. Mr. Ballard is a top fund-raiser for Mr. Trump. Mr. Haselwood had been an in-house lobbyist at Reynolds before joining Ballard Partners this year.

A spokesman for Ballard Partners declined to comment.

Advertisement

While public health experts consider e-cigarettes a less harmful alternative to tobacco-burning cigarettes, the new guidance circumvents a scientific review process the F.D.A. had previously defended up to the Supreme Court. The disregarded procedures were meant to ensure approval of only those products shown in studies to help cigarette smokers transition to vapes without attracting a new generation of nicotine users.

The guidance also could allow higher nicotine levels in nicotine pouches. It includes a pledge to prioritize efforts to stop the import of illegal foreign vapes, an idea that has bipartisan support in Congress.

Taken together, the policy changes could help companies like Altria and Reynolds gain market share considered central to the survival of the industry.

The market for vapes and nicotine pouches, like Zyn, is about 30 million people in the United States, on par with the number of cigarette smokers. While the nicotine pouch market is rapidly growing, cigarettes still account for about $50.8 billion, or nearly 70 percent of the annual tobacco sales in the United States, according to a Goldman Sachs research report. Vape sales have lagged amid competition from illicit products.

In recent years, the F.D.A. has moved glacially to approve e-cigarettes, authorizing only those in tobacco or menthol flavors, including some sold by Reynolds and Altria. Unapproved Chinese vapes have poured into the United States, feeding a thriving illicit market with flavors like peach slush and watermelon ice. Last year, industry executives have said, illicit fruit-flavored vapes made up 60 percent of the e-cigarette market.

Advertisement

When Mr. Trump mounted his bid to return to the White House, some in the tobacco industry went all in, hoping he would loosen regulations on vapes and abandon plans by the Biden administration to ban menthol cigarettes and crack down on other cigarette sales.

Mr. Trump in some ways makes for an unlikely savior for the tobacco industry. He has never smoked, but he pledged during his 2024 campaign to “save vaping again.”

Through a subsidiary, Reynolds, which is the biggest seller of menthol cigarettes, donated $10 million to a super PAC backing Mr. Trump’s campaign, according to campaign finance filings. There is no public record of the subsidiary donating to groups supporting Mr. Biden or the campaign of former Vice President Kamala Harris.

Mr. Ballard, whose firm has been paid more than $4.4 million by Reynolds since the beginning of 2017, arranged for Mr. Trump to have dinner during the campaign with Reynolds executives in New York, according to a person familiar with the interactions. The executives urged Mr. Trump to oppose the menthol cigarette ban and expressed concern about Chinese vapes.

Reynolds executives including Mr. Raborn and Mr. Haselwood were such a presence around the campaign that Mr. Trump took to calling them “my tobacco guys,” according to the person familiar with the interactions and a book coauthored by a New York Times reporter and published last year.

Advertisement

When Mr. Trump won, the rest of the industry jockeyed to show support.

Altria donated $1 million to his inaugural committee; the Vapor Technology Association donated $1.25 million; and a subsidiary of Philip Morris donated $500,000.

On Mr. Trump’s second full day in office, his administration withdrew the proposed ban on menthol cigarettes, an initiative the Biden administration had already mostly abandoned. Mr. Trump’s team also set aside a Biden-era proposal to sharply restrict nicotine in cigarettes, an effort meant to speed the transition away from a product known to be deadly.

In applauding the withdrawal of the menthol ban, Billy Gifford, the chief executive of Altria, told investors on an April 2025 earnings call that “we’re hopeful that that activity and momentum continues.”

The courtship intensified.

Advertisement

Reynolds pitched in another $3 million to a different Trump-backed super PAC, while Altria and Juul each donated $1 million.

And Reynolds and Altria each donated to the effort to raise private funds to build a new White House ballroom. Mr. Raborn of Reynolds and Mr. Walker of Altria were invited to a dinner at the White House in October for donors who gave $2.5 million or more, as was Mr. Ballard.

Tadeu Marroco, the chief executive of British American Tobacco, which owns Reynolds American, predicted to investors earlier this year that the Trump administration would clamp down on illegal vapes, saying “it’s very encouraging, the signs that the new administration is giving to address that.”

The companies’ lobbying strategy also has reached into the states, where they are pushing for so-called “registry laws” — of which there are now more than a dozen including in Florida, Virginia and Pennsylvania. Many of those laws restrict e-cigarette sales to only vapes on a list from the F.D.A.

The guidance released last week said it would create such a list.

Advertisement

Sheryl Gay Stolberg contributed reporting.

Continue Reading
Advertisement

Trending